Septal ablation, a valid alternative for obstructive hypertrophic cardiomyopathy

Original title: Survival of Patients ≤50 Years Alter Alcohol Septal Ablation for Hypertrofic Obstructive Cardiomyopathy. Reference: Josef Veselka, et al. Canadian Journal of Cardiology 2014,30:634-638

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) is the surgical septal myomectomy nevertheless, currently arose several studies reporting a favourable evolution and comparable to surgery with septal ablation (AS). 75 patients under 50 years of age with HCM, 85 procedures were performed. The primary endpoint was all-cause mortality, and the secondary was all-cause mortality or defibrillator implant.

Average age of the population was 42 ± 7 years all symptomatic with a gradient of 73 ± 38 mmHg and the basal septum thickness of 23 ± 6 mm. Post procedure, 8% had complete AV block and 2.7% transient AV block with a need for permanent pacemaker of 6.7%. Follow-up was performed in all patients at 5.1 years showing significant improvement in functional class associated with a fall in the gradient outflow tract and decreased thickness in the basal septum.

Four patients died during follow-up (1 to 30 days by sudden death, 1 by stroke, 1 from gastrointestinal bleeding and 1 for cancer), only two were attributed to the underlying disease. Survival rates at 1, 3 and 5 years were 97%, 94%, and 94%, respectively, not being able to identify predictors of mortality in the multivariate analysis. The risk of death or need for a defibrillator was not associated with post septal ablation gradient.

Conclusion: 

This study in patients with obstructive hypertrophic cardiomyopathy (HCM) under 50 years who received septal ablation suggests a low risk of death from any cause or defibrillator implant in the long-term monitoring. 

Editorial comment 

Myomectomy remains the best strategy for those patients who are operated; however, this study showed a favourable evolution and comparable to surgery in young people; septal ablation is a less aggressive behaviour. More research is needed. 

Courtesy Dr. Carlos Fava
Interventional cardiologist
Favaloro Foundation
Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....